Lannett Co Inc (NYSE:LCI): Institutional Investor Sentiment Down to 0.73

July 17, 2017 - By Ellis Scott

 Lannett Co Inc (NYSE:LCI): Institutional Investor Sentiment Down to 0.73

Sentiment for Lannett Co Inc (NYSE:LCI)

Lannett Co Inc (NYSE:LCI) institutional sentiment decreased to 0.73 in Q4 2016. Its down -0.63, from 1.36 in 2016Q3. The ratio dived, as 65 investment professionals started new or increased positions, while 89 decreased and sold holdings in Lannett Co Inc. The investment professionals in our partner’s database now possess: 32.74 million shares, up from 28.61 million shares in 2016Q3. Also, the number of investment professionals holding Lannett Co Inc in their top 10 positions increased from 1 to 3 for an increase of 2. Sold All: 43 Reduced: 46 Increased: 45 New Position: 20.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The company has market cap of $892.75 million. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. It currently has negative earnings. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

The stock decreased 0.88% or $0.2 on July 17, reaching $22.5. About 420,937 shares traded. Lannett Company, Inc. (NYSE:LCI) has declined 2.16% since July 17, 2016 and is downtrending. It has underperformed by 18.86% the S&P500.

Analysts await Lannett Company, Inc. (NYSE:LCI) to report earnings on August, 22. They expect $0.86 earnings per share, up 17.81 % or $0.13 from last year’s $0.73 per share. LCI’s profit will be $34.12M for 6.54 P/E if the $0.86 EPS becomes a reality. After $0.77 actual earnings per share reported by Lannett Company, Inc. for the previous quarter, Wall Street now forecasts 11.69 % EPS growth.

Telemus Capital Llc holds 18.43% of its portfolio in Lannett Company, Inc. for 6.16 million shares. Zpr Investment Management owns 190,710 shares or 7.29% of their US portfolio. Moreover, Muhlenkamp & Co Inc has 3.51% invested in the company for 504,379 shares. The Pennsylvania-based Snow Capital Management Lp has invested 2.51% in the stock. Deerfield Management Co, a New York-based fund reported 2.01 million shares.#img1#

Since January 1, 0001, it had 1 insider buy, and 0 selling transactions for $200,000 activity.

Lannett Company, Inc. (NYSE:LCI) Ratings Coverage

Ratings analysis reveals 67% of Lannett’s analysts are positive. Out of 9 Wall Street analysts rating Lannett, 6 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $3 while the high is $70. The stock’s average target of $42.07 is 86.98% above today’s ($22.5) share price. LCI was included in 21 notes of analysts from July 21, 2015. The firm has “Buy” rating by Roth Capital given on Thursday, March 24. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Strong-Buy” rating by Zacks on Monday, September 7. The company was maintained on Thursday, September 3 by TH Capital. The company was initiated on Tuesday, July 21 by Susquehanna. Craig Hallum downgraded the stock to “Hold” rating in Thursday, November 5 report. Raymond James maintained the stock with “Outperform” rating in Wednesday, August 24 report. The firm has “Buy” rating by Roth Capital given on Friday, March 11. As per Thursday, August 27, the company rating was maintained by Craig Hallum. The rating was maintained by Roth Capital with “Buy” on Wednesday, August 26. Deutsche Bank initiated the stock with “Hold” rating in Wednesday, June 29 report.

More notable recent Lannett Company, Inc. (NYSE:LCI) news were published by: which released: “Lannett: Bullish Possibilities Despite Massive Short Interest” on June 27, 2017, also with their article: “Lannett Appoints Samuel H. Israel As General Counsel” published on July 17, 2017, published: “Lannett Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL” on July 14, 2017. More interesting news about Lannett Company, Inc. (NYSE:LCI) were released by: and their article: “Here’s Why Lannett Company, Inc. Is Having a Lousy Day” published on May 03, 2017 as well as‘s news article titled: “Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone …” with publication date: June 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.